News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

OS benefit of adjuvant osimertinib in resected EGFR-mutated NSCLC persists at 8th year
7 hours ago
byElvira Manzano
Adjuvant osimertinib continues to demonstrate an overall survival (OS) benefit over placebo in patients with resected EGFR-mutated (exon 19 del/L858R) non-small cell lung cancer (NSCLC), according to the 8-year exploratory analysis of the phase III ADAURA trial presented at WCLC 2026.
7 hours ago

Quadruple regimen shows promise as first-line treatment for extrapulmonary NEC
12 Nov 2026
byStephen Padilla
First-line treatment with surufatinib combined with serplulimab and etoposide/cisplatin (EP) regimen exhibits antitumour activity with manageable safety in patients with advanced or metastatic extrapulmonary neuroendocrine carcinoma (NEC), reports a study presented at ESMO Congress 2026.
12 Nov 2026






